Zentalis Pharmaceuticals, Inc. (ZNTL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Kimberly L. Blackwell
Employees:
180
530 SEVENTH AVENUE, SUITE 2201, NEW YORK, NY 10018
(212) 433-3791

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 627.526 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.58
Price to Revenue0.0 Debt to Equity0.0 EBITDA-221.772 Million
Price to Book Value6.6209 Operating Margin0.0 Enterprise Value1.763 Billion
Current Ratio6.928 EPS Growth-12.485 Quick Ratio6.655
1 Yr BETA 1.8109 52-week High/Low 59.65 / 17.33 Profit Margin0.0
Operating Cash Flow Growth-55.2926 Altman Z-Score11.4164 Free Cash Flow to Firm -152.905 Million
Earnings Report2023-02-23
View SEC Filings from ZNTL instead.

View recent insider trading info

Funds Holding ZNTL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ZNTL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-09-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-07-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    20 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GALLAGHER CAM PRESIDENT

    • Officer
    • Director
    352,011 2023-01-17 14

    EPPERLY MELISSA B, CHIEF FINANCIAL OFFICER

    • Officer
    297,543 2022-10-03 4

    BUNKER KEVIN D. CHIEF SCIENTIFIC OFFICER

    • Officer
    959,460 2022-10-03 10

    BROWNSTEIN CARRIE CHIEF MEDICAL OFFICER

    • Officer
    0 2022-10-03 2

    SKVARKA JAN

    • Director
    36,606 2022-09-09 2

    PAUL ANDREA GENERAL COUNSEL

    • Officer
    0 2022-08-01 2

    JOHNSON DAVID MICHAEL

    • Director
    108,330 2022-06-08 1

    KARIUKI ENOCH

    • Director
    21,817 2022-06-08 1

    MATRIX CAPITAL MANAGEMENT COMPANY, LP

    GOEL DAVID E.

    • 10% Owner
    9,199,973 2022-05-18 1

    BLACKWELL KIMBERLY PRESIDENT & CEO

    • Officer
    • Director
    2,136,011 2022-05-16 1

    SUN ANTHONY Y PRESIDENT & CEO

    • Officer
    • Director
    2,592,141 2022-04-04 4

    VOLIOTIS DIMITRIS SVP, CLINICAL DEVELOPMENT

    • Officer
    56,791 2022-02-10 1

    PINTO ALEXIS CHIEF LEGAL OFFICER

    • Officer
    83,660 2022-02-10 1

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    No longer subject to file 2020-12-01 0

    RECURIUM EQUITY, LLC

    • 10% Owner
    No longer subject to file 2020-10-28 0

    TAKHAR KARAN S.

    • Director
    0 2020-04-03 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GALLAGHER CAM - Director - Officer PRESIDENT

    2023-01-18 17:15:03 -0500 2023-01-17 S 9,500 $24.11 d 352,511 direct yes 2.5032 -0.8632 2.5032 2 -0.8632 6

    GALLAGHER CAM - Director - Officer PRESIDENT

    2023-01-18 17:15:03 -0500 2023-01-17 S 500 $24.87 d 352,011 direct yes 2.5032 -0.8632 2.5032 2 -0.8632 6

    GALLAGHER CAM - Director - Officer PRESIDENT

    2023-01-05 19:16:31 -0500 2023-01-05 S 9,700 $21.01 d 362,311 direct yes -12.6355 17.586 17.586 6 -12.6355 2

    GALLAGHER CAM - Director - Officer PRESIDENT

    2023-01-05 19:16:31 -0500 2023-01-05 S 300 $21.46 d 362,011 direct yes -12.6355 17.586 17.586 6 -12.6355 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 22:15:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 21:45:04 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 21:15:04 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 20:45:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 20:15:04 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 19:45:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 19:15:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 18:45:04 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 18:15:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 17:45:03 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 17:15:04 UTC 3.5549 0.7651 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 16:45:03 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 16:15:03 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 15:45:03 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 15:15:04 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 14:45:04 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 14:15:03 UTC 3.5743 0.7457 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 13:45:03 UTC 3.8902 0.4298 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 13:15:03 UTC 3.8902 0.4298 400000
    ZENTALIS PHARMACEUTICALS INC ZNTL 2023-01-27 12:45:03 UTC 3.8902 0.4298 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Long/Short Equity Fund ZNTL -344.0 shares, $-28225.2 2021-11-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund ZNTL -2903.0 shares, $-62878.98 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments